Explanipedia

Consultation report – considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries Open

Ana Belén Ibarz-Pavón, Marie-Christine Bielsky, Rubina Bose, Marco Cavaleri, John A. Crump , et al. · 2025

Enteric fever caused by Salmonella enterica serovars Typhi and Paratyphi A and, to a lesser extent, S. Paratyphi B and C, remains a significant cause of mortality and morbidity in resource-constrained settings. Typhoid conjugate vaccines (…

Author Correction: Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization Open

Yugenia K. Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C. Allende, David C. Kaslow · 2025

Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization Open

Yugenia K. Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C. Allende, David C. Kaslow · 2024

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023 Open

Marco Cavaleri, David C. Kaslow, Eric Boateng, Wilbur H. Chen, Christopher Chiu , et al. · 2024

Many aspects of Controlled Human Infection Models (CHIMs, also known as human challenge studies and human infection studies) have been discussed extensively, including Good Manufacturing Practice (GMP) production of the challenge agent, CH…

Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries Open

Birgitte Giersing, Richard Isbrucker, David C. Kaslow, Marco Cavaleri, Norman W. Baylor , et al. · 2023

Shigellosis causes considerable public health burden, leading to excess deaths as well as acute and chronic consequences, particularly among children living in low-income and middle-income countries (LMICs). Several Shigella vaccine candid…

The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making Open

Raymond Hutubessy, Jeremy A. Lauer, Birgitte Giersing, So Yoon Sim, Mark Jit , et al. · 2023

Accelerating access for all through research and innovation in immunization: Recommendations from Strategic Priority 7 of the Immunization Agenda 2030 Open

David Sarley, Angela Hwang, B. Fenton Hall, Andrew Ford, Birgitte Giersing , et al. · 2022

Research and innovation have been fundamental to many of the successes in immunization thus far, and will play important roles in the future success of Immunization Agenda 2030 (IA2030). Strategic Priority 7 (SP7) of IA2030, which addresse…

Why vaccinate children against COVID-19? Open

David C. Kaslow, Carolina Batista, María Elena Bottazzi, Önder Ergönül, J. Peter Figueroa , et al. · 2022

Any guidance on vaccine use prioritization, including booster dose policies, cannot ignore the current, ongoing profound inequities in global COVID-19 vaccine access and coverage. While higher-income countries expand their vaccination prog…

KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine Open

Corey Casper, Lawrence Corey, Jeffrey I. Cohen, Blossom Damania, Anne A. Gershon , et al. · 2022

Seven viruses cause at least 15% of the total cancer burden. Viral cancers have been described as the “low-hanging fruit” that can be potentially prevented or treated by new vaccines that would alter the course of global human cancer. Kapo…

Standardization of Epidemiological Surveillance of Invasive Group A Streptococcal Infections Open

Kate M Miller, Theresa Lamagni, Thomas Cherian, Jeffrey Cannon, Tom Parks , et al. · 2022

Invasive group A streptococcal (Strep A) infections occur when Streptococcus pyogenes, also known as beta-hemolytic group A Streptococcus, invades a normally sterile site in the body. This article provides guidelines for establishing surve…

Standardization of Epidemiological Surveillance of Group A Streptococcal Cellulitis Open

Kate M Miller, Theresa Lamagni, Roderick J. Hay, Jeffrey Cannon, Michael Marks , et al. · 2022

Cellulitis is an acute bacterial infection of the dermis and subcutaneous tissue usually found complicating a wound, ulcer, or dermatosis. This article provides guidelines for the surveillance of cellulitis. The primary objectives of cellu…

Standardization of Epidemiological Surveillance of Acute Poststreptococcal Glomerulonephritis Open

Kate M Miller, Chris Van Beneden, Malcolm McDonald, Thel K. Hla, William Wong , et al. · 2022

Acute poststreptococcal glomerulonephritis (APSGN) is an immune complex-induced glomerulonephritis that develops as a sequela of streptococcal infections. This article provides guidelines for the surveillance of APSGN due to group A Strept…

Standardization of Epidemiological Surveillance of Group A Streptococcal Impetigo Open

Kate M Miller, Jonathan R. Carapetis, Thomas Cherian, Roderick J. Hay, Michael Marks , et al. · 2022

Impetigo is a highly contagious bacterial infection of the superficial layer of skin. Impetigo is caused by group A Streptococcus (Strep A) and Staphylococcus aureus, alone or in combination, with the former predominating in many tropical …

Standardization of Epidemiological Surveillance of Group A Streptococcal Pharyngitis Open

Kate M Miller, Robert R. Tanz, Stanford T. Shulman, Jonathan R. Carapetis, Thomas Cherian , et al. · 2022

Pharyngitis, more commonly known as sore throat, is caused by viral and/or bacterial infections. Group A Streptococcus (Strep A) is the most common bacterial cause of pharyngitis. Strep A pharyngitis is an acute, self-limiting disease but …

Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022 Open

H Prudden, Sharon L. Achilles, Celina Schocken, Nathalie Broutet, Karen Canfell , et al. · 2022

Who to vaccinate first? A peek at decision-making in a pandemic Open

Ruth Faden, Alejandro Cravioto, Joachim Hombach, David C. Kaslow, Sonali Kochhar , et al. · 2022

Efforts to Develop Pfs25 Vaccines Open

David C. Kaslow · 2022

Acknowledging the fallibilities of recalling events from more than three decades ago, the recollection of Richard Carter’s impact on the identification and development of Pfs25, a major surface protein of Plasmodium falciparum zygotes and …

Leveraging mRNA Platform Technology to Accelerate Development of Vaccines for Some Emerging and Neglected Tropical Diseases Through Local Vaccine Production Open

Erin Sparrow, Mateusz Hasso-Agopsowicz, David C. Kaslow, Kavita Singh, R. Prabhakar Rao , et al. · 2022

The mRNA vaccine technology platform may enable rapid response to some emerging infectious diseases (EIDs), as demonstrated through the COVID-19 pandemic. Beyond the role it could play in future EID response, mRNA technology also could hav…

Should we vaccinate against long-COVID? Open

Peter J. Hotez, Carolina Batista, Yanis Ben Amor, Önder Ergönül, Peter Figueroa , et al. · 2022

The primary goal of current COVID-19 vaccination programs is preventing hospitalizations and deaths from acute disease. However, an important additional role for vaccination could be in preventing or treating post-acute COVID-19 syndrome, …

A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases Open

Hannah C. Moore, Jeffrey Cannon, David C. Kaslow, Theresa Lamagni, Asha C Bowen , et al. · 2022

Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine deve…

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. Open

Edward P K Parker, S. Desai, Melanie Marti, Hanna Nohynek, David C. Kaslow , et al. · 2022

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants – Key considerations for global use Open

Erin Sparrow, Ifedayo Adetifa, Nathorn Chaiyakunapruk, Thomas Cherian, Deshayne B. Fell , et al. · 2022

Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review Open

Edward P K Parker, Shalini Desai, Melanie Marti, Hanna Nohynek, David C. Kaslow , et al. · 2022

Individuals with compromised immune systems, whether because of immunodeficiency or immunosuppressive therapy, are among those most susceptible to COVID-19. In fact, people who are immunocompromised are doubly susceptible. On the one hand,…

Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case Open

Sonali Kochhar, Dráurio Barreira, Pauline Beattie, Marco Cavaleri, Alejandro Cravioto , et al. · 2022

The silent and dangerous inequity around access to COVID-19 testing: A call to action Open

Carolina Batista, Peter J. Hotez, a b, Kim J.H., David C. Kaslow , et al. · 2022

The COVID-19 pandemic is a public health crisis of unprecedented proportions. Despite unparalleled rates of vaccination and mass testing in certain parts of the world, the virus rages on. Since SARS-CoV-2, the virus that causes COVID-19, w…

The silent and dangerous inequity around access to COVID-19 testing: A call to action Open

Carolina Batista, Peter J. Hotez, Yanis Ben Amor, Jérôme H. Kim, David C. Kaslow , et al. · 2021

The COVID-19 pandemic is a public health crisis of unprecedented proportions. Despite unparalleled rates of vaccination and mass testing in certain parts of the world, the virus rages on. Since SARS-CoV-2, the virus that causes COVID-19, w…

Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed Open

J. Peter Figueroa, Peter J. Hotez, Carolina Batista, Yanis Ben Amor, Önder Ergönül , et al. · 2021

Peter Figueroa and co-authors advocate for equity in the worldwide provision of COVID-19 vaccines.

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic Open

Peter J. Hotez, Carolina Batista, Yanis Ben Amor, Önder Ergönül, J. Peter Figueroa , et al. · 2021

Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment Open

Denise Naniche, Peter J. Hotez, María Elena Bottazzi, Önder Ergönül, J. Peter Figueroa , et al. · 2021

As of March 2021, over 40 COVID-19 vaccine candidates were either in phase 3 clinical trials or had received conditional approval for emergency use [[1]McGill COVID19 Vaccine Tracker Team – COVID19 vaccine tracker . [cited 2021 Mar 8]. Ava…

Urgent needs to accelerate the race for COVID-19 therapeutics Open

Carolina Batista, Shmuel Shoham, Önder Ergönül, Peter J. Hotez, María Elena Bottazzi , et al. · 2021

On December 8, 2020, a 91-year-old woman made history as the first person to receive the COVID-19 vaccine in the United Kingdom. Worldwide vaccination coverage will take time, especially in low-middle-income countries (LMICs) where access …

David C. Kaslow YOU? Author Swipe